J Everly

1000 total citations
10 papers, 760 citations indexed

About

J Everly is a scholar working on Transplantation, Hematology and Immunology. According to data from OpenAlex, J Everly has authored 10 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Transplantation, 4 papers in Hematology and 4 papers in Immunology. Recurrent topics in J Everly's work include Renal Transplantation Outcomes and Treatments (6 papers), Complement system in diseases (2 papers) and Multiple Myeloma Research and Treatments (2 papers). J Everly is often cited by papers focused on Renal Transplantation Outcomes and Treatments (6 papers), Complement system in diseases (2 papers) and Multiple Myeloma Research and Treatments (2 papers). J Everly collaborates with scholars based in United States. J Everly's co-authors include E. Steve Woodle, Rita R. Alloway, Amit D. Tevar, Paul Brailey, Prabir Roy‐Chaudhury, G. Mogilishetty, Adele Rike, Lois J. Arend, Amit Govil and R. C. Walsh and has published in prestigious journals such as Transplantation, The Oncologist and Expert Opinion on Biological Therapy.

In The Last Decade

J Everly

10 papers receiving 741 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J Everly United States	7	496	316	211	187	123	10	760
Anne Cesbron‐Gautier France	11	472 1.0×	250 0.8×	346 1.6×	50 0.3×	98 0.8×	26	698
Paul Brailey United States	13	885 1.8×	481 1.5×	358 1.7×	72 0.4×	258 2.1×	24	1.1k
Rens Kraaijeveld Netherlands	15	370 0.7×	170 0.5×	317 1.5×	86 0.5×	33 0.3×	27	650
E. Felber Germany	9	299 0.6×	168 0.5×	272 1.3×	57 0.3×	170 1.4×	11	527
Elaine Reed United States	5	320 0.6×	308 1.0×	124 0.6×	68 0.4×	44 0.4×	8	520
Kazuo Mizutani United States	11	531 1.1×	368 1.2×	233 1.1×	29 0.2×	149 1.2×	30	744
Afzal Nikaein United States	13	263 0.5×	245 0.8×	290 1.4×	68 0.4×	21 0.2×	35	693
Supreet Sethi United States	14	397 0.8×	255 0.8×	116 0.5×	35 0.2×	149 1.2×	24	559
Hugo Kaneku United States	21	1.2k 2.5×	1.1k 3.4×	304 1.4×	43 0.2×	92 0.7×	41	1.5k
Jasper Callemeyn Belgium	18	664 1.3×	429 1.4×	178 0.8×	40 0.2×	197 1.6×	35	867

Countries citing papers authored by J Everly

Since Specialization

Citations

This map shows the geographic impact of J Everly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Everly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Everly more than expected).

Fields of papers citing papers by J Everly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Everly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Everly. The network helps show where J Everly may publish in the future.

Co-authorship network of co-authors of J Everly

This figure shows the co-authorship network connecting the top 25 collaborators of J Everly. A scholar is included among the top collaborators of J Everly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Everly. J Everly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Ryan, Charles J., Philip J. Saylor, J Everly, & Oliver Sartor. (2014). Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data. The Oncologist. 19(10). 1012–1018. 14 indexed citations

2.

Everly, Matthew J., J Everly, & Paul I. Terasaki. (2011). Role of proteasome inhibition in sensitized transplant candidates.. PubMed. 124(5). 771–4. 4 indexed citations

3.

Walsh, R. C., J Everly, Paul Brailey, et al.. (2010). Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection. Transplantation. 89(3). 277–284. 146 indexed citations

4.

Miao, Yun, J Everly, Thomas G. Gross, et al.. (2009). De Novo Cancers Arising in Organ Transplant Recipients are Associated With Adverse Outcomes Compared With the General Population. Transplantation. 87(9). 1347–1359. 155 indexed citations

5.

Everly, J, R. C. Walsh, Rita R. Alloway, & E. Steve Woodle. (2009). Proteasome inhibition for antibody-mediated rejection. Current Opinion in Organ Transplantation. 14(6). 662–666. 65 indexed citations

6.

Everly, Matthew J., J Everly, B. Süßkind, et al.. (2009). Proteasome Inhibition Reduces Donor-Specific Antibody Levels. Transplantation Proceedings. 41(1). 105–107. 46 indexed citations

7.

Everly, Matthew J., J Everly, Brian Susskind, et al.. (2008). Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. Transplantation. 86(12). 1754–1761. 306 indexed citations

8.

Everly, Matthew J., J Everly, Paul Brailey, et al.. (2008). PROTEASOME INHIBITION EFFECTIVELY TREATS ACUTE CELLULAR REJECTION, ANTIBODY MEDIATED REJECTION, AND PROVIDES LONG-TERM REDUCTION OF DONOR SPECIFIC ANTIBODIES. Transplantation. 86(2S). 68–69. 1 indexed citations

9.

Woodle, E. Steve, Rita R. Alloway, Adele Rike, et al.. (2007). Corticosteroid elimination: the Cincinnati experience.. PubMed. 51–60. 3 indexed citations

10.

Everly, J & Sagar Lonial. (2005). Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. Expert Opinion on Biological Therapy. 5(3). 293–311. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact